Established in Clonmel, Tipperary in 2018 by Sharon Cunningham and Orlaith Ryan, Shorla Pharma Ltd is a specialty pharmaceutical company with an advanced pipeline of innovative oncology drugs for women’s, orphan and pediatric cancers.
Shorla Pharma are dedicated to developing novel products that are clinically impactful focusing on the pharmaceutical formulation to ensure high quality, greater dose flexibility, easier administration and better acceptance of medicines.
Expansion to the U.S.
Shorla Pharma are rapidly building its U.S. team, headquartered in Cambridge, MA. The company has an advanced pipeline of oncology products to treat a number of unmet patient needs.
“It’s an honor to bring Shorla’s life-changing treatments to patients in the U.S.,” said Sharon Cunningham, CEO and Co-founder of Shorla Pharma. “This is an important step in our commercialization planning. As a company breaking new ground in the treatment of cancers, with our first product targeted for launch later in 2021, we believe now is the right time to establish our U.S. operations.”
Future for the Company
In 2020, Shorla Pharma was named Local Enterprise of the Year at the ‘Irish Times’ awards.
Shorla Pharma is now one step closer to launching its leukemia treatment in the US as it seeks FDA approval to launch its leukemia treatment.
The company’s development pipeline also includes a drug for treating breast and ovarian cancers, and an oral solution developed to treat patients with glioblastoma who have difficulty swallowing.
Source: Ireland south East
Call me back 
